Association of Pap Smear Abnormalities with Autoimmune Disorders
Recently, it is hypothesized that there might be an association between immunological disorders and cervical premalignant and malignant abnormalities. Related studies have been generally focused on some particular autoimmune disease, specially the Systemic Lupus Erythematosus (SLE). This study aimed at comparing the rate of Pap smear abnormalities in female patients with autoimmune diseases and normal counterparts. In a case-control setting, 118 female patients with various autoimmune diseases (the case group) and 118 healthy female counterparts (the control group) were recruited in Tabriz Imam Reza Teaching Centre in a 24 months period of time. The two groups were matched for demographics and known risk factors of cervical malignancy. Frequencies of abnormal Pap smear testing were compared between the two groups. The autoimmune disorders were SLE (74 patients), rheumatoid arthritis or RA (32 patients), systemic sclerosis or SS (7 patients) and ankylosing spondylitis or AS (5 patients) in the case group. Frequency of abnormal Pap smear testing was significantly higher in the case group comparing with that in the controls (7.6% vs. 1.7%; p = 0.03). Frequency of abnormal Pap smear testing was higher in the patients with SLE (8.1%) and RA (9.3%) comparing with that in the controls; However, these differences were marginally nonsignificant (p = 0.06 and p = 0.07, respectively). Frequency of cases with abnormal Pap smear testing was not statistically different between the autoimmune disorders (p = 0.99). Based on these findings and in conclusion, there might be an association between the autoimmune disorders and occurrence of premalignant or malignant lesions in cervix. Further studies with larger samples sizes are recommended.
Received: July 30, 2011;
Accepted: September 22, 2011;
Published: October 13, 2011
Cervical cancer is the second most common malignancy among women all over the
world (Gonzalez-Losa et al., 2006; Hussain
et al., 2009; Sultana et al., 2011)
and a leading cause of death in this group (Tambunan et
al., 2007). There are known risk factors in this regard including early
and multipartner sexual contacts, smoking, use of Oral Contraceptive Pill (OCP)
and immunosuppressive medications. It is clear that screening of women could
decrease the incidence of cervical cancer dramatically by detection of early
premalignant changes in the tissue (Rosai, 2004). One
of the best screening modalities for cervical cancer is the clinical cytologic
approach and the Pap smear test is an accurate noninvasive method in this regard
(Beckmann, 2005; Shobeiri and Nazari,
2007; Moosavi et al., 2008; Yavari
et al., 2009). It is previously hypothesized that there might be
an association between disorders of immune system and increased risk of cervical
cancer (Gibbs et al., 2008). Nandigam
(2006) reported a case of cervical cancer with immunologic thrombocytopenia.
There are a number of studies in the literature indicating higher frequency
of abnormalities in Pap smears of women with Systemic Lupus Erythematosus (SLE)
comparing with healthy counterparts (Tani et al.,
2011; Tam et al., 2011). There is no consensus
on the etiology of this association between immunological diseases and cervical
cancer. Infection with Human Papillomavirus (HPV) (Lee et
al., 2010; Klumb et al., 2010a), immunosuppressive
therapy (Klumb et al., 2010b) or a causal association
(Mercado, 2009; Bernatsky et
al., 2006) have been proposed in this regard. To the best of our knowledge,
there is not any study in the literature assessing association of immunological
disorders (not a particular one like SLE) and cervical cancer based on the result
of Pap smear. This study aimed at determining the frequency of Pap smear abnormality
in a group of women with different autoimmune diseases in comparison with a
well-matched group of healthy counterparts.
MATERIALS AND METHODS
Subjects: In this case-control study, 118 females patients with different autoimmune disorders and 118 matched healthy females were enrolled in Tabriz Imam Reza Educational Centre in a 24 month period of time from June 2009 to June 2011. The autoimmune disorders were definitely diagnosed by two different skilled specialists. The autoimmune diseases (in the case group) were SLE (systemic lupus erythematosus) in 74 patients, RA (rheumatoid arthritis) in 32 patients, SS (systemic sclerosis) in 7 patients and AS (ankylosing spondylitis) in 5 patients were compared with 118 healthy counterparts (the control group).
Pap smear: Pap smear testing was performed by a skilled pathologist skilled in gynecological diseases and evaluation was carried out by Liquid-Based Cytology (LBC) for cervical cancer screening. The pathologist was blind to the grouping of subjects.
Pap smear testing was performed in these steps:
||Transferring of smear: The content of smear was deployed
in a box of preservatives. This box included an alcohol-based material for
preserving cells for long times (2-18 months) in the room temperature
||Preparation of slides: The thin layer technology was employed for
this purpose. By using a special detergent instead of applying filters,
blood, mucus and any debris were cleansed. Then the preparation was centrifuged.
The precipitated pellet was mixed by cell-base solution. After vibration,
this liquid was used to prepare the final slide
The specimen adequacy of Pap smears were judged according to the patients
demographics, clinical information, adequate number of squamous epithelial cell
and adequate number of endocervical cells in transformation zone including 5
groups of endocervical or squamous metaplastic cells (Atkinson
and Silverman, 1998).
Study design and variables: The results of Pap smear testing were compared between the case and control groups. This study was approved by the Ethics Committee of Tabriz University of Medical Sciences. The studied data were patients demographics, obstetrical history and risk factors of cervical cancer.
Statistical analysis: Statistical evaluation was made using SPSS for Windows V 18.0 (SPSS Inc., Il, USA). Data were shown as frequency (percentage) or Mean±Standard Deviation (SD). Independent samples T, chi-square and Fishers Exact tests were employed for statistical analysis. The p-values less than 0.05 were regarded as significant.
General data and the studied variables including age, marriage status, education level, career, nulliparity, gravidity, parity, history of abortion, OCP use and smoking status were comparable between the cases and the controls, between the SLE patients and the controls and between the RA patients and the controls. These variables were also comparable between the SS/AS patients and the controls were comparable except for the history of abortion which was significantly higher in the SS/AS group comparing with the controls. The age ranged between 32-41 years in the case group (32-41 in the SLE group, 32-39 years in the RA group and 33-39 years in the SS/AS group) and 34-40 years in the controls.
The educational level ranged between 8-14 years in the case group (8-14 years in the SLE group, 9-13 years in the RA group and 8-13 years in the SS/AS group) and 8-14 years in the controls.
The gravidity ranged between 0-5 in the case group (0-5 in the SLE group, 1-4 in the RA group and 0-4 in the SS/AS group) and 0-5 in the controls.
The parity ranged between 0-3 in the case group (0-3 in the SLE group, 0-3 in the RA group and 1-3 in the SS/AS group) and 0-3 in the controls. These data are summarized and compared between the mentioned groups in Table 1.
A positive Pap smear result was present in 9 patients in the case group including
6 patients in the SLE group and 3 patients in the RA group. There was no case
with the positive Pap smear result in the SS/AS group. In the control group,
there were 2 patients with positive Pap smear result. The rate of positive Pap
smears was significantly higher in the patients with autoimmune diseases than
in the healthy counterparts (7.6% vs. 1.7%; p = 0.03). Although, the frequencies
of patients with positive Pap smear results in the SLE (8.1%) and RA (9.3%)
groups were not significantly different from that in the controls, both differences
were marginal (p = 0.06 and 0.07, respectively). The rate of abnormal Pap smear
results were not significantly different between the groups with various autoimmune
diseases (p = 0.56). Percentages of subjects with abnormal Pap smear result
are shown in Fig. 1.
All the positive Pap smear results were of the Atypical Squamous Cells of Undetermined Significance (ASCUS) type except for 2 subjects in the case group which were of the human papillomavirus (HPV) type.
|| Comparison of general data in different studied groups with
|Data are shown as Mean±Standard deviation or frequency
(percentage). p<0.05 is considered statistically significant. The only
significant difference was between the SS/AS and the control groups with
regard to the history f abortion. *Case vs. control, **SLE (systemic lupus
erythematosus) vs. control, ***RA (Rheumatoid arthritis) vs. control, ****SS/AS
(systemic sclerosis/ankylosing spondylitis) vs. control. OCP: Oral contraceptive
||Percentages of patients with positive Pap smear results in
the studied groups, RA: Rheumatoid arthritis. SLE: Systemic lupus erythematosus.
The rate of subjects with positive Pap smear was significantly higher in
the case group vs. the controls (p = 0.03). The comparisons between the
SLE groups vs. the controls (p = 0.06) and between the RA group vs. the
controls (p = 0.07) were insignificant but borderline in this regard. The
difference was not significantly significant between the groups with various
autoimmune diseases (p = 0.56)
In the present study, the rate of positive Pap smears was significantly higher
in the patients with autoimmune diseases. Although, the frequencies of patients
with positive Pap smear results in the SLE and RA groups were not significantly
different from that in the controls, both differences were marginal (Fig.
1). It should be noticed that the known risk factors of cervical cancer
such as smoking, nulliparity and OCP use were comparable between the patients
and controls and so the confounding factors were eliminated in this study. To
the best of our knowledge, the available reports are only confined to those
assessing possible association between the cervical cancer and the SLE by now.
Blumenfeld et al. (1994) studied 39 female patients
with SLE and reported that the rate of cases with positive Pap smear is significantly
higher in this group comparing with age-matched healthy females (35.9% vs. 5%).
Comparing with our results, the rate of abnormal Pap smears is higher in both
the SLE patients and the normal subjects in the mentioned study. This controversy
might be due to presence of possible confounding factors which were not controlled
in the Blumenfelds series. Nevertheless, in both reports the rate of abnormal
Pap smears was higher in the SLE patients comparing with normal subjects. Berthier
et al. (1999) also reported similar results in a group of female
patients with SLE. So, the result of the present study regarding a higher frequency
of abnormal Pap smears in the SLE patients is in line with the mentioned report.
The rate of positive Pap smear was 24.1% in female patients with SLE vs. 9.6%
in controls in another series by Dhar et al. (2001).
These rates are also higher than those in the present study. Another justification
for this heterogeneity may be ethnical and racial differences between different
populations. The corresponding rates were 16.5% vs. 5.7% in another series by
Tam et al. (2004). This difference might be also
justified by racial differences. Other possible etiologies in this regard are
the differences in sample size, risk factors of cervical cancer, method of performing
Pap smear and level of examiners experience. On the other hand, it is
not exactly known if an abnormal result of Pap smear testing is due to pathophysiology
of the SLE disease itself or a consequence of related therapies (Sultan
et al., 2000; Bateman et al., 2000;
Ognenovski et al., 2004). It is thought that
the immunosuppressive treatments make patients vulnerable to infections and
simultaneously hinder resolving a present infection in patients (Bernatsky
et al., 2004). This condition is a rich environment for different
microbial (such as Chlamydia) and viral (such as HPV) infections (Gopalkrishna
et al., 2000; Finan et al., 2002;
Schiffman et al., 1993; Berthier
et al., 1999). Nevertheless, some other studies concluded that association
of autoimmune disease (SLE) with higher incidence of cervical cancer is independent
of immunosuppressive therapy (Blumenfeld et al.,
1994; Tam et al., 2004). In the present study,
it was not possible to definitely evaluate the effect of previous immunotherapy;
because it was only based on the patients report which could be influenced
by the recall bias or misreport. Further more controlled longitudinal studies
may elucidate the issue. In the present study, there was not a significant difference
between various groups of autoimmune diseases with regard to the frequency of
abnormal Pap smear results (p = 0.56) (Fig. 1). Abu-Shakra
et al. (1996) proposed that occurrence of cervical cancer is less
in SLE disease comparing with that in RA and SS. This is in contradiction with
finding of the present study. It should be noticed that in the mentioned study
the rate of cervical cancer has been compared between the groups with autoimmune
diseases and this may be different from the abnormal Pap smear result. Small
sample size specially in the SS/AS group is another justification of this heterogeneity.
Further studies with larger sample sized are required in this regard.
Based on finding in this study, autoimmune diseases may increase risk of cervical cancer in these patients. This hazard is independent of conventional risk factors for such malignancies. So, it is highly recommended that relevant screening approaches such as Pap smear testing are better considered in all patients with autoimmune diseases regularly.
1: Abu-Shakra, M., D.D. Gladman and M.B., Urowitz, 1996. Malignancy in systemic lupus erythematosus. Arthritis. Rheum., 39: 1050-1054.
2: Atkinson, B.F. and J.F. Silverman, 1998. Atlas of Difficult Diagnoses in Cytopathology. 1st Edn., Saunders, USA, ISBN-10: 0721640761.
3: Bateman, H., Y. Yazici, L. Leff, M. Peterson and S.A. Paget, 2000. Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: A preliminary study. Lupus, 9: 542-544.
4: Beckmann, C.R.B., 2005. Obstetrics and Gynecology. 5th Edn., Lippincott Williams and Wilkins, USA, ISBN-13: 978-0781758062.
5: Bernatsky, S.R., G.S. Cooper, C. Mill, R. Ramsey-Goldman, A.E. Clarke and C.A., Pineau, 2006. Cancer screening in patients with systemic lupus erythematosus. J. Rheumatol., 33: 45-49.
6: Bernatsky, S., R. Ramsey-Goldman, C. Gordon, L. Joseph and J.F. Boivin et al., 2004. Factors associated with abnormal Pap results in systemic lupus erythematosus. Rheumatology, 43: 1386-1389.
7: Berthier, S., C. Mougin, P. Vercherin, H. Desmurs, H. Gil, B. de Wazieres and J.L., Dupond, 1999. Does a particular risk associated with papillomavirus infections exist in women with lupus. Rev. Med. Interne., 20: 128-132.
8: Blumenfeld, Z., M. Lorber, N. Yoffe and Y. Scharf, 1994. Systemic lupus erythematosus: Predisposition for uterine cervical dysplasia. Lupus, 3: 59-61.
9: Dhar, J.P., D. Kmak, R. Bhan, L. Pishorodi, J. Ager and R.J., Sokol, 2001. Abnormal cervicovaginal cytology in women with lupus: A retrospective cohort study. Gynecol. Oncol., 82: 4-6.
10: Gonzalez-Losa, M.D.R., A.C. Hidalgo-Martinez, L. Manzano-Cabrera, A. Estrada-Saldivar and M. Puerto-Solis, 2006. Absence of DNA human papillomavirus type 16 in mexican women with normal pap smear. Int. J. Virol., 2: 59-62.
CrossRef | Direct Link |
11: Finan, R.R., H. Tamim and W.Y. Almawi, 2002. Identification of chlamydia trachomatis DNA in Human Papillomavirus (HPV) positive women with normal and abnormal cytology. Arch. Gynecol. Obstet., 266: 168-177.
12: Gibbs, R.S., B.Y. Karlan, A.F. Haney and I.E. Nygaard, 2008. Danforth's Obstetrics and Gynecology. 10th Edn., Lippincott Williams and Wilkins, USA., ISBN-10: 078176937X.
13: Gopalkrishna, V., N. Aggarwal, V.L. Malhotra, R.V. Koranne, V.P. Mohan, A. Mittal and B.C., Das, 2000. Chlamydia trachomatis and human papillomavirus infection in Indian women with sexually transmitted diseases and cervical precancerous and cancerous lesions. Clin. Microbiol. Infect., 6: 88-93.
14: Klumb, E.M., M.L. Araujo, Jr., G.R. Jesus, D.B. Santos, A.V. Oliveira, E.M. Albuquerque and J.M. Macedo, 2010. Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression?. J. Clin. Rheumatol., 16: 153-157.
15: Klumb, E.M., A.C. Pinto, G.R. Jesus, M. Araujo, Jr. and L. Jascone et al., 2010. Are women with lupus at higher risk of HPV infection?. Lupus, 19: 1485-1491.
16: Lee, Y.H., J.Y. Choe, S.H. Park, Y.W. Park and S.S. Lee et al., 2010. Prevalence of human papilloma virus infections and cervical cytological abnormalities among Korean women with systemic lupus erythematosus. J. Korean. Med. Sci., 25: 1431-1437.
17: Mercado, U., 2009. Squamous intraepithlelial lesions in women's lupus. Ginecol. Obstet. Mex., 77: 423-427.
18: Moosavi, S.S., S. Soltani and M. Shaikhpoor, 2008. A comparison between cytological method and PCR in the diagnosis of HPV infection among patients with cervical cancer. Biotechnology, 7: 798-802.
CrossRef | Direct Link |
19: Nandigam, K., 2006. Severe immune thrombocytopenia in a case of cervical carcinoma. Int. J. Cancer Res., 2: 159-160.
CrossRef | Direct Link |
20: Ognenovski, V.M., W. Marder, E.C. Somers, C.M. Johnston, J.G. Farrehi, S.M. Selvaggi and W.J. McCune, 2004. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J. Rheumatol., 31: 1763-1767.
21: Rosai, J., 2004. Rosai and Ackerman's Surgical Pathology. 9th Edn., Mosby, USA.
22: Hussain, A., S. Sasidharan, T. Ahmed, M. Ahmed and C. Sharma, 2009. Clove (Syzygium aromaticum) extract potentiates gemcitabine cytotoxic effect on human cervical cancer cell line. Int. J. Cancer Res., 5: 95-104.
CrossRef | Direct Link |
23: Schiffman, M.H., H.M. Bauer, R.N. Hoover, A.G. Glass and D.M. Cadell et al., 1993. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J. Nat. Cancer Inst., 85: 958-964.
24: Shobeiri, F. and M. Nazari, 2007. Assessment of cervical erosion in Hamedan city, Iran. Pak. J. Biol. Sci., 10: 3470-3472.
CrossRef | PubMed | Direct Link |
25: Sultan, S.M., Y. Ioannou and D.A. Isenberg, 2000. Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatol., 39: 1147-1152.
26: Sultana, S.A., S. Kiranmayee, V.K. Bammidi, A.P. Shaik and K. Jamil, 2011. Introduction to the role of fragile histidine triad (fhit) gene in cancer: A review of literature with special emphasis on cervical carcinoma. Int. J. Cancer Res., 7: 99-113.
CrossRef | Direct Link |
27: Tambunan, U.S.F., H.W. Butar-Butar, R. Umbas and Z. Hidayah, 2007. Conserved region analysis of oncogenic human Papillomavirus genome. Biotechnology, 6: 93-96.
CrossRef | Direct Link |
28: Tam, L.S., A.Y. Chan, P.K. Chan, A.R. Chang and E.K. Li, 2004. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: Association with human papillomavirus infection. Arthritis. Rheum., 50: 3619-3625.
29: Tam, L.S., P.K. Chan, S.C. Ho, M.Y. Yu and S.F. Yim et al., 2011. Risk factors for squamous intraepithelial lesions in systemic lupus erythematosus: A prospective cohort study. Arthritis. Care. Res., 63: 269-276.
30: Tani, C., L. Carli, M. Mosca, C. Baldini and A. Consensi et al., 2011. Adherence to cervical cancer screening in an Italian SLE cohort. Reumatismo, 63: 11-17.
31: Yavari, M., M. Haghkhah, M.R. Ahmadi, H.R. Gheisari and S. Nazifi, 2009. Comparison of cervical and uterine cytology between different classification of postpartum endometritis and bacterial isolates in holstein dairy cows. Int. J. Dairy Sci.. 4: 19-26.
CrossRef | Direct Link |